PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Oliceridine Matches Remifentanil Analgesia in Ventilated ICU Patients, With Fewer Post-Extubation Respiratory Events

oliceridineremifentanilG protein-biased mu-opioid agonistopioid analgesiamechanical ventilationICUanalgesia-first sedationCPOTrespiratory depressionextubationnon-inferiority RCTARDS Critical Care / ICU

Background Information

Oliceridine matches remifentanil's analgesia with enhanced safety in the ICU.

Analgesic management during mechanical ventilation is crucial for patient safety and comfort. Oliceridine showed a non-inferior analgesic effect to remifentanil with fewer adverse drug reactions and respiratory issues. This study suggests oliceridine as a potential alternative to remifentanil, with a better safety profile in managing pain for ventilated patients. Oliceridine offers effective analgesia with fewer adverse effects compared to remifentanil in ICU settings.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Lu S, Luo JC, Li Q, Lei XY, Ding XF, Dong QL, Hu QH, Zhu WT, Zhang X, Duan LL, Lv S, Ran QF, Ma L, Guo C, Dong JJ, Yang YQ, Xu L, Yang J, Wang J, Qiu LF, Jing BC, Jia FJ, Zhang L, Tang QB, Ibarra-Estrada M, Luo MH, Pan C, Huang XB, Martin-Loeches I

Citation: Lu S, Luo JC, Li Q, et al. Efficacy and safety of oliceridine versus remifentanil for analgesia in mechanically ventilated critically ill adults (CO-ROAM): a multicenter, assessor-blinded, non-inferiority randomized controlled trial. Intensive care medicine. 2026. doi:10.1007/s00134-026-08643-8

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.